Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | STK17B | O94768 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19810802 | 0.83 | MAOA (0.47) | — | |
| SCHEMBL18020472 | 0.82 | SIGMAR1 (0.48) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL19820979 | 0.74 | CYP2D6 (0.33) | — | |
| SCHEMBL19810652 | 0.73 | MAOA (0.44) | CYP2A6 | |
| SCHEMBL17413663 | 0.73 | SIGMAR1 (0.53) | SIGMAR1CHRNB2CHRNA4CYP2A6 | |
| SCHEMBL17413660 | 0.73 | SIGMAR1 (0.53) | SIGMAR1CHRNB2CHRNA4CYP2A6 | |
| SCHEMBL24631730 | 0.72 | MAPK14 (0.41) | — | |
| SCHEMBL24631449 | 0.72 | AHR (0.43) | — | |
| SCHEMBL19820992 | 0.72 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL18020367 | 0.71 | STK17B (0.31) | STK17B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256468-B1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-04-08 | — | — | EP | disclosed |
| US-10183917-B2 | Tricyclic compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183917-B2 | Tricyclic compounds and uses thereof in medicine | NR1H4, SLC10A1, SLC10A2 | SIGMAR1 980/4885CHRNB2 2602/4885CHRNA4 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.